Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.

Adult Antibodies, Monoclonal / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Hematologic Neoplasms / drug therapy Humans Immunotherapy / methods Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy Leukemia, Myeloid, Acute / drug therapy Multiple Myeloma / drug therapy
Acute myeloid leukemia Chronic lymphocytic leukemia Geriatric oncology Multiple myeloma Novel agents Older adults

Journal

Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967

Informations de publication

Date de publication:
08 03 2019
Historique:
pmc-release: 08 03 2020
entrez: 9 3 2019
pubmed: 9 3 2019
medline: 14 7 2020
Statut: epublish

Résumé

Hematologic malignancies are common and difficult to treat in older adults. In this review, we focus on recent updates in diseases with several novel agents relevant to older adults-acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). In AML, CPX-351 offers a new induction chemotherapy for secondary AML that prolongs survival, and venetoclax and IDH inhibitors are efficacious and well tolerated. In CLL, chemoimmunotherapy is being replaced by monoclonal antibodies and small molecule inhibitors that are more effective and better tolerated. In MM, new immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies have expanded treatment options for older patients. The introduction of novel agents has dramatically shifted the landscape of therapeutic options for older adults with hematologic malignancies. Clinical trials in older adults are needed to expand treatment options for these patients.

Identifiants

DOI: 10.1007/s11912-019-0778-2 PMID: 30848394 PMC: PMC6438699
pubmed: 30848394
doi: 10.1007/s11912-019-0778-2
pii: 10.1007/s11912-019-0778-2
pmc: PMC6438699
mid: NIHMS1017049
doi:

Substances chimiques

Antibodies, Monoclonal 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Subventions

Organisme : NIA NIH HHS
ID : T32 AG000212
Pays : United States

Références

Hematol Oncol Clin North Am. 2000 Feb;14(1):235-50, xi
pubmed: 10680080
Blood. 2004 Nov 15;104(10):3052-7
pubmed: 15265788
Blood. 2006 May 1;107(9):3481-5
pubmed: 16455952
Lancet. 2006 Mar 11;367(9513):825-31
pubmed: 16530576
Blood. 2008 Mar 1;111(5):2521-6
pubmed: 17901246
Lancet. 2007 Oct 6;370(9594):1209-18
pubmed: 17920916
Haematologica. 2008 Apr;93(4):560-5
pubmed: 18322252
Blood. 2008 Aug 15;112(4):975-80
pubmed: 18411418
N Engl J Med. 2008 Aug 28;359(9):906-17
pubmed: 18753647
Blood. 2009 Apr 30;113(18):4179-87
pubmed: 19008455
J Clin Oncol. 2009 Aug 1;27(22):3664-70
pubmed: 19451428
Blood. 2009 Oct 15;114(16):3382-91
pubmed: 19605849
J Clin Oncol. 2010 Feb 1;28(4):562-9
pubmed: 20026804
J Clin Oncol. 2010 Apr 10;28(11):1878-87
pubmed: 20212255
Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
Lancet. 2010 Dec 11;376(9757):2000-8
pubmed: 21131036
Leuk Lymphoma. 2012 Jan;53(1):118-22
pubmed: 21780997
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685
J Clin Oncol. 2011 Nov 20;29(33):4417-23
pubmed: 21969499
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
J Am Geriatr Soc. 2011 Oct;59(10):1837-46
pubmed: 22091497
N Engl J Med. 2012 May 10;366(19):1759-69
pubmed: 22571200
J Clin Oncol. 2012 Jul 20;30(21):2670-7
pubmed: 22689805
J Clin Oncol. 1990 Feb;8(2):272-9
pubmed: 2299370
Blood. 2013 May 23;121(21):4287-94
pubmed: 23550038
Lancet Oncol. 2014 Jan;15(1):48-58
pubmed: 24332241
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Leuk Res. 2014 Mar;38(3):275-83
pubmed: 24439052
N Engl J Med. 2014 Mar 13;370(11):997-1007
pubmed: 24450857
Blood. 2014 May 22;123(21):3239-46
pubmed: 24687088
J Clin Oncol. 1989 Sep;7(9):1268-74
pubmed: 2475589
J Clin Oncol. 2014 Jun 20;32(18):1919-26
pubmed: 24841975
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803
pubmed: 25046833
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
N Engl J Med. 2014 Sep 4;371(10):906-17
pubmed: 25184863
Lancet Oncol. 2014 Oct;15(11):1195-206
pubmed: 25242045
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
Ann Hematol. 2015 Jul;94(7):1127-38
pubmed: 25791241
Lancet. 2015 May 9;385(9980):1873-83
pubmed: 25882396
Bone Marrow Transplant. 2015 Aug;50(8):1075-82
pubmed: 25961765
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
J Clin Oncol. 2015 Nov 20;33(33):3921-9
pubmed: 26056177
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
J Clin Oncol. 2015 Oct 20;33(30):3459-66
pubmed: 26282661
Leuk Lymphoma. 2016;57(4):789-96
pubmed: 26377031
Blood. 2015 Dec 17;126(25):2686-94
pubmed: 26472751
Blood. 2016 Jan 21;127(3):303-9
pubmed: 26492934
J Clin Oncol. 2015 Dec 10;33(35):4167-75
pubmed: 26527780
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Blood. 2016 Mar 3;127(9):1102-8
pubmed: 26729895
N Engl J Med. 2016 Apr 28;374(17):1621-34
pubmed: 27119237
Lancet Oncol. 2016 Jun;17(6):768-778
pubmed: 27178240
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
Lancet Oncol. 2016 Jul;17(7):928-942
pubmed: 27216274
J Clin Oncol. 2016 Oct 20;34(30):3609-3617
pubmed: 27325857
Haematologica. 2016 Sep;101(9):1110-9
pubmed: 27479825
Cancer. 2016 Dec 15;122(24):3865-3872
pubmed: 27529755
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Haematologica. 2016 Nov;101(11):1390-1397
pubmed: 27612987
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Leukemia. 2017 Feb;31(2):272-281
pubmed: 27721426
Ann Oncol. 2017 Feb 1;28(2):218-227
pubmed: 27803007
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
Blood. 2017 May 11;129(19):2702-2705
pubmed: 28325865
J Clin Oncol. 2017 Aug 1;35(22):2473-2481
pubmed: 28426350
Blood. 2017 Aug 10;130(6):722-731
pubmed: 28588020
Lancet Oncol. 2017 Oct;18(10):1338-1347
pubmed: 28870615
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Blood Adv. 2017 Jan 4;1(4):282-287
pubmed: 29296944
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Leukemia. 2018 Aug;32(8):1697-1712
pubmed: 29880892
Haematologica. 2018 Nov;103(11):1889-1898
pubmed: 29976743
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Am J Hematol. 2018 Nov;93(11):1318-1326
pubmed: 30094870
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Leukemia. 2019 Feb;33(2):379-389
pubmed: 30555165

Auteurs

Li-Wen Huang (LW)

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 505 Parnassus Ave, Hematology/Oncology Office, M1286, San Francisco, CA, 94143, USA. li-wen.huang@ucsf.edu.

Sandy W Wong (SW)

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 400 Parnassus Ave, Box 1270, San Francisco, CA, 94143, USA.

Charalambos Andreadis (C)

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 400 Parnassus Ave, Box 0324, San Francisco, CA, 94143, USA.

Rebecca L Olin (RL)

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, 400 Parnassus Ave, Box 0324, San Francisco, CA, 94143, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Tumeurs hématologiques › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie chronique lymphocytaire à cellules B › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Updates on Hematologic Malignancies in the...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Updates on Hematologic Malignancies in the...